IL10 and colitis: From a mechanistic point of view, we have recently shown that therapeutic FMT treatment in experimental models of acute colitis not only introduced beneficial modifications in the dysbiotic microbiota, but also impacted on frequencies and cytokine profiles of both innate and adaptive immune cells, as a consequence of an IL10-dependent amelioration of the inflammatory status [19].